CD19 and neoplasm: Despite its poor ability to bind CD19, the superior target cell avidity and anti-tumor activity of the G02 CAR suggests that it can recruit additional adhesive mechanisms to achieve productive target cell engagement, perhaps via enhanced immune synapse formation.